James H. Stanker - 05 Apr 2024 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Reporting relationship: Chief Financial Officer
Issuer ticker: PCSA
Reported as of: 05 Apr 2024
Net transaction value: -$1,927
SEC form: 4
Accepted by SEC: 02 Aug 2024, 17:31:53 UTC
Prior SEC filing: 12 Apr 2024
Source filing: View source filing
Reporting owner signature: /s/ James H. Stanker by Michael B. Kirwan, as Attorney-in-Fact

Key filing fact

James H. Stanker filed Form 4 for Processa Pharmaceuticals, Inc. (PCSA) on 02 Aug 2024.

Key facts

This page summarizes James H. Stanker's Form 4 filing for Processa Pharmaceuticals, Inc. (PCSA).
8 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 02 Aug 2024, 17:31.

Change

Previous filing in this sequence was filed on 12 Apr 2024.
Current net transaction value: -$1,927.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PCSA transaction

Common Stock

Options Exercise

Transaction value
Shares: +1,675
Change %: +34%
Price
Shares after: 6,638
Date: 05 Apr 2024
Ownership: Direct
Footnotes: F1

PCSA transaction

Common Stock

Tax liability

Transaction value: $1,445
Shares: -518
Change %: -7.8%
Price: $2.79
Shares after: 6,120
Date: 05 Apr 2024
Ownership: Direct

PCSA transaction

Common Stock

Options Exercise

Transaction value
Shares: +644
Change %: +11%
Price
Shares after: 6,764
Date: 10 Jul 2024
Ownership: Direct
Footnotes: F1

PCSA transaction

Common Stock

Tax liability

Transaction value: $482
Shares: -282
Change %: -4.2%
Price: $1.71
Shares after: 6,482
Date: 10 Jul 2024
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCSA transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +3,077
Change %: +13%
Price: $0.000000
Shares after: 26,470
Date: 28 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,077
Exercise price: $0.000000
Footnotes: F2

PCSA transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +2,307
Change %: +8.7%
Price: $0.000000
Shares after: 28,777
Date: 28 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,307
Exercise price: $0.000000
Footnotes: F3

PCSA transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +385
Change %: +1.3%
Price: $0.000000
Shares after: 29,162
Date: 28 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 385
Exercise price: $0.000000
Footnotes: F4

PCSA transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +385
Change %: +1.3%
Price: $0.000000
Shares after: 29,547
Date: 28 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 385
Exercise price: $0.000000
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Distribution of vested restricted shares.

Footnote F2

Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025.

Footnote F3

Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027.

Footnote F4

Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.